CMS 340B Cut: $4.85B Hospital Shock
A proposed 40% cut to 340B drug payments will hit safety-net hospitals and the most vulnerable patients at the worst possible moment.
On July 2, 2026, CMS released its Outpatient Prospective Payment System proposed rule for calendar year 2027. Buried inside 1,400 pages of regulatory language was a single payment rate change that will hit America's most fragile hospitals harder than any single Medicare policy in a decade.
The agency proposed cutting 340B drug payments from ASP+6% to ASP-33.4%. That is a 39.4 percentage point drop in reimbursement. The total estimated impact: $4.85 billion in reduced revenue for the hospitals, federally qualified health centers, and rural health clinics that serve the country's most vulnerable patients.
This is not a rounding error. This is a structural defunding of the safety net.
What CMS Just Did
The 340B Drug Pricing Program, created by Congress in 1992, allows covered entities to purchase outpatient drugs from manufacturers at deeply discounted prices. The program exists because safety-net providers carry a disproportionate share of uncompensated care, treat higher rates of complex and chronically ill patients, and operate with margins that leave almost no room for financial shocks.
For decades, covered entities purchased drugs at 340B prices and billed Medicare at the standard ASP+6% rate. The spread between those two numbers funded preventive services, care coordination programs, charity care, and specialty services that could not otherwise exist at these institutions.
In 2018, CMS first cut the 340B rate to ASP-22.5%, citing overpayment concerns. Courts ultimately ruled that cut invalid. In the years since, CMS restored the rate and accumulated an estimated $9 billion in obligations to covered entities for the years the cut was in effect. The new proposed rule addresses that recoupment while simultaneously cutting the ongoing 340B rate to its lowest level in the program's history.
The Math Behind the Shock
Under the current rate of ASP+6%, a hospital that purchases a drug at 340B discount prices and bills Medicare gets reimbursed at roughly 6% above the Average Sales Price. Under the proposed ASP-33.4% rate, that same drug bills at 33.4% below ASP. On a drug with a $200 ASP, the difference is $78 per unit. Multiplied across millions of drug administrations per year at thousands of covered entities, that produces the $4.85 billion annual revenue loss estimate.
CMS argues this is justified by two things: first, that the existing 340B rate overcompensated covered entities relative to their actual acquisition costs; and second, that the $2.3 billion in annual budget-neutral redistribution to other outpatient services will benefit those same hospitals through a higher base payment rate.
That second argument does not survive contact with the data. The 2.4% net outpatient base rate increase flows to all hospitals proportionally. Safety-net hospitals, which serve lower-income patients with fewer commercially insured visits, gain less from a base rate increase than from the 340B spread they are losing. The math does not work for hospitals that run on the thinnest margins.
Why This Hits Safety-Net Hospitals So Hard
Not all hospitals participate in 340B. To qualify, a hospital must meet the definition of a disproportionate share hospital (DSH) or operate as a critical access hospital, children's hospital, or freestanding cancer center, among other categories. These are precisely the institutions that serve high percentages of Medicaid, uninsured, and complex-need patients.
The concentration of the cut matters. CMS's own estimate acknowledges that the $4.85 billion reduction falls almost entirely on covered entities. Non-340B hospitals are largely unaffected and actually benefit from the budget-neutral redistribution. This is, at its core, a transfer of Medicare payments from hospitals that serve the poor to hospitals that do not.
Ashley Thompson, Senior Vice President of Public Policy at the American Hospital Association, put it plainly: 'This enormous cut will make drugs less affordable for America's most vulnerable patients and threaten funding for programs these patients depend on.'
The Budget Neutrality Shell Game
CMS frames its 340B cuts as part of a budget-neutral adjustment: the $4.85 billion in 340B reductions is offset by a higher base outpatient rate that benefits all hospitals. This framing is technically accurate and substantively misleading.
Budget neutrality means total Medicare outpatient spending stays approximately flat. It does not mean the impact is distributed evenly. A hospital that relies heavily on 340B drug revenue loses far more than it gains from the base rate increase. A hospital with minimal 340B exposure gains from the base rate increase without taking any cut.
The recoupment acceleration compounds this. CMS proposes to increase the pace of repaying covered entities for the 2018-2022 period from 0.5% per year to 3% per year. In practice, this changes nothing about the structural loss from the new ongoing payment rate, and the additional recoupment amounts are a one-time offset against a permanent annual $4.85 billion reduction.
Who Wins and Who Loses
The distributional effects of this rule are not ambiguous. They follow directly from the structure of who participates in 340B and how outpatient drug revenue flows through the system.
The winners are hospitals with low 340B participation rates, particularly academic medical centers in suburban markets and community hospitals with commercially-insured patient bases. They benefit from the base rate increase without absorbing the 340B cut. Medicare beneficiaries save an estimated $1.15 billion in lower drug cost-sharing. Pharmaceutical manufacturers benefit because fewer 340B-eligible purchases reduce their total program obligations.
The losers are concentrated among institutions that have the least capacity to absorb financial shocks. Safety-net DSH hospitals, which often operate on 0.5-1.5% operating margins, will face a revenue reduction that could force service cuts, program closures, or in the worst cases, facility closures. FQHCs and rural health clinics face similar dynamics. The patients they serve, who have limited alternatives and rely on these facilities for access to complex specialty care and medication programs, are the ultimate losers.
What Happens If This Goes Through
The 340B spread does not just pad hospital balance sheets. America's Essential Hospitals has documented how these funds flow: into uncompensated care programs, specialty services, care coordination for high-need patients, patient drug assistance programs, and the operational infrastructure that allows safety-net hospitals to remain financially viable.
America's Essential Hospitals also raised a critical methodological concern: CMS based its rate-setting analysis on data from less than 25% of 340B covered entities. That is a significant sampling limitation for a rule with this level of financial impact. The adequacy of that data analysis should be a central focus of public comments.
If the cut goes through at the proposed level, the most immediate effect will be on the most complex and expensive services at safety-net hospitals. Oncology, specialty pharmacy, infusion services, and HIV/AIDS programs are disproportionately dependent on 340B drug revenue. These are precisely the services that low-income patients have no other access point for.
The longer-term effect is an accelerating consolidation of those services into better-funded institutions in wealthier markets, with a corresponding reduction in access for the patients who most need them. This is not a speculative concern. It is the documented pattern from the 2018 cut, which preceded service reductions at multiple DSH hospitals before the legal reversal.
The 340B Counterargument: What CMS Gets Right
Intellectual honesty requires acknowledging that the 340B program has been criticized, including from credible sources, for allowing revenue capture without commensurate documentation of patient benefit. The Government Accountability Office and others have noted that the program lacks robust requirements for covered entities to demonstrate that 340B savings directly flow to patient care.
CMS is not wrong to note that the gap between acquisition cost and Medicare reimbursement has generated substantial revenue for some covered entities. The question is whether a blunt payment rate cut is the appropriate policy instrument, or whether targeted transparency requirements and program integrity safeguards would achieve the same goal without collateral damage to the hospitals most dependent on the spread.
What Safety-Net Leaders Should Do Right Now
The comment period closes August 31, 2026. That deadline is not a formality. CMS is required to respond to substantive comments in the final rule, and a well-organized comment campaign from covered entities, patient advocates, and state associations has historically influenced the final rule's scope.
Document the specific programs funded by 340B at your institution. Generic impact statements carry less weight than precise data on service lines, staffing, and patient populations at risk.
Challenge the data methodology. CMS relied on less than 25% of covered entities in its analysis. Comments that directly address this limitation, with supporting data from your institution, have procedural and legal weight.
Quantify the distributional impact. Show specifically how the budget-neutral redistribution fails to offset the 340B cut for hospitals with your patient mix.
Coordinate with state hospital associations. A coordinated comment campaign from multiple institutions is more difficult to dismiss than individual submissions.
Submit comments at regulations.gov under the CY 2027 OPPS proposed rule docket. The deadline is August 31, 2026.
Engage your Congressional delegation. Congressional oversight letters and hearings have changed the trajectory of 340B policy before.
The August 31 Deadline
The 2027 OPPS proposed rule is not final. CMS will publish a final rule later this fall, and that final rule will reflect both the substantive comments received and the political environment around the proposal.
The 2018 cut ultimately took years of litigation to reverse. The institutions that survived that period were the ones that had the financial reserves and operational flexibility to absorb the revenue loss temporarily. Many safety-net hospitals do not have that runway in 2026. The margins are thinner. The patient populations are more complex. The post-pandemic operating environment has left fewer reserves to draw on.
This makes the August 31 comment deadline more important, not less. If the rule is finalized at the proposed cut level, the legal and administrative remedies available afterward are slower and more uncertain than the regulatory process right now.
The $4.85 billion question is not whether CMS has the authority to cut 340B rates. It is whether the proposed cut is the right policy, at the right level, applied to the right institutions, in a way that serves Medicare beneficiaries and the communities that depend on safety-net care. The comment period is the mechanism for demanding that answer. Use it.
Oatmeal Health tracks healthcare policy, AI, and the business of care. If this analysis was useful, share it with a colleague navigating the same policy environment. The comment deadline is August 31, 2026 at regulations.gov.